Delivery Service Partner for the Gram-negative Antibiotic Discovery Innovator consortium
The Gates Foundation, Novo Nordisk Foundation and Wellcome have launched a new initiative, The Gram-Negative Antibiotic Discovery Innovator (Gr-ADI), to drive innovation in early drug discovery for Gram-negative pathogens.
Gr-ADI will function as a consortium, bringing together the portfolio of projects and working collectively across multiple funders, research institutions and industry partners. Success of the consortium depends on cohesive and collaborative working, which requires careful management of the projects. This includes facilitating and fostering an open environment where researchers are encouraged and motivated to share learnings, insights and data.
We are seeking a supplier who will be able to provide the following:
- Project management of the Gr-ADI portfolio.
- Monitor progress at both the project and consortium level.
- Co-ordinate meetings of the consortium within the governance structure of Gr-ADI.
- Foster an environment of collaboration to enable the consortium to function effectively.
Commissioning team:
Eligibility:
Open to all, subject to skills and experience as outlined in the RFP
Expression of interest:
15 August 2025
Questions and answers deadline:
15 August 2025
Submissions deadline:
5 September 2025